Major Signaling Pathways Involved in Breast Cancer

作者: Saba Wasim Aziz , Moammir Hasan Aziz

DOI: 10.1007/978-1-4614-5647-6_4

关键词:

摘要: Breast cancer is the leading cause of cancer-related mortality among women worldwide. Significant advancement has been made recently in delineating cellular processes and signaling pathways involved breast cancer. Cross-communication between different allows cells to identify respond appropriately extracellular environment. Cancer development a gradual complex process resulting from any disruption these that ultimately generates signals defining required biological response. The epidermal growth factor receptor (EGFR) family tyrosine kinases represents both key regulators normal as well critical players variety cancers including aim this book chapter give broad overview signal transduction networks such Ras/Raf/MEK/ERK PI3K/AKT are controlled by EGFR superfamily receptors. elucidation will further provide new insights understanding pathogenesis targeting combat against development, progression, metastasis.

参考文章(147)
R. Marais, Y. Light, H.F. Paterson, C.J. Marshall, Ras recruits Raf‐1 to the plasma membrane for activation by tyrosine phosphorylation. The EMBO Journal. ,vol. 14, pp. 3136- 3145 ,(1995) , 10.1002/J.1460-2075.1995.TB07316.X
Alberto M Martelli, Camilla Evangelisti, Francesca Chiarini, James A McCubrey, None, The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget. ,vol. 1, pp. 89- 103 ,(2010) , 10.18632/ONCOTARGET.114
Ali Naderi, Michelle Meyer, Dennis H. Dowhan, Cross-regulation between FOXA1 and ErbB2 Signaling in Estrogen Receptor-Negative Breast Cancer Neoplasia. ,vol. 14, pp. 283- 296 ,(2012) , 10.1593/NEO.12294
Deric L. Wheeler, Toni M. Brand, Mari Iida, Chunrong Li, The nuclear epidermal growth factor receptor signaling network and its role in cancer Discovery Medicine. ,vol. 12, pp. 419- 432 ,(2011)
Fabio Puglisi, Alessandro Marco Minisini, Carmine De Angelis, Grazia Arpino, Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. Drugs. ,vol. 72, pp. 1175- 1193 ,(2012) , 10.2165/11634000-000000000-00000
G Carpenter, S Cohen, Epidermal growth factor. Journal of Biological Chemistry. ,vol. 265, pp. 7709- 7712 ,(1972) , 10.1016/S0021-9258(19)38983-5
Marina Holgado-Madruga, David K. Moscatello, Jaclyn A. Biegel, George Gunn, Roberta L. Hayes, Albert J. Wong, Gloria Ramirez, Philip W. Zoltick, Andrew K. Godwin, Frequent Expression of a Mutant Epidermal Growth Factor Receptor in Multiple Human Tumors Cancer Research. ,vol. 55, pp. 5536- 5539 ,(1995)
L S Steelman, S L Abrams, J Whelan, F E Bertrand, D E Ludwig, J Bäsecke, M Libra, F Stivala, M Milella, A Tafuri, P Lunghi, A Bonati, A M Martelli, J A McCubrey, Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia Leukemia. ,vol. 22, pp. 686- 707 ,(2008) , 10.1038/LEU.2008.26
Michael F. Press, Dennis J. Slamon, Kerry J. Flom, Jinha Park, Jian-Yuan Zhou, Leslie Bernstein, Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens Journal of Clinical Oncology. ,vol. 20, pp. 3095- 3105 ,(2002) , 10.1200/JCO.2002.09.094
Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073